Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9786028 | 0.85 | AOC3 (0.39) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL10648349 | 0.85 | AOC3 (0.39) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL6356440 | 0.84 | AOC3 (0.38) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL150075 | 0.84 | CA1 (0.40) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL4160051 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBCYP1A2KDM4ETSHR | |
| SCHEMBL7273837 | 0.82 | SLC2A1 (0.42) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL8248932 | 0.82 | BCHE (0.48) | SMN1; SMN2POLBKDM4ETSHRMAPT | |
| SCHEMBL28771054 | 0.81 | AOC3 (0.36) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL7274049 | 0.81 | AOC3 (0.36) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL954640 | 0.81 | MEN1 (0.47) | POLBKDM4ETSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013026942-A1 | TUBULIN BINDING AGENTS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2013-02-28 | — | — | WO | disclosed |
| US-20070142399-A1 | Dual function drugs and uses thereof | PSYCHIATRIC GENOMICS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142399-A1 | Dual function drugs and uses thereof | PSYCHIATRIC GENOMICS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1066227-B1 | PROCESS OF PREPARING DISCOTIC LIQUID CRYSTALLINE COMPOUNDS | MERCK PATENT GMBH (DE) | 2005-12-28 | — | — | EP | disclosed |
| EP-1523556-A1 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG-1 RECEPTOR | SRI INTERNATIONAL (US) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004009816-A1 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG-1 RECEPTOR | CERETEK LLC (US) | 2004-01-29 | — | — | WO | disclosed |
| US-6534135-B1 | Process of preparing discotic liquid crystalline compounds | MERCK PATENT GESELLSCHAFT (DE) | 2003-03-18 | — | — | US | disclosed |
| EP-1066227-A1 | PROCESS OF PREPARING DISCOTIC LIQUID CRYSTALLINE COMPOUNDS | MERCK PATENT GmbH (DE) | 2001-01-10 | — | — | EP | disclosed |
| EP-0957092-A1 | Ring-closed dihydropyridines and their use in the preparation of pharmaceutical compositions | Boehringer Ingelheim Pharma KG (DE) | 1999-11-17 | — | — | EP | disclosed |
| WO-1999048844-A1 | PROCESS OF PREPARING DISCOTIC LIQUID CRYSTALLINE COMPOUNDS | MERCK PATENT GMBH (DE) | 1999-09-30 | — | — | WO | disclosed |
| US-5861412-A | CARDIOPROTECTIVE AGENTS, CEREBROPROTECTIVE AGENTS, AGENTS FOR TREATING CHRONIC INFLAMMATORY PROCESSES, ANTIPROLIFERATIVE AGENTS AND AS AGENTS FOR TREATING ULCERATIVE COLITIS AND CROHN'S DISEASE | BOEHRINGER INGELHEIM KG (DE) | 1999-01-19 | — | — | US | disclosed |
| US-5674878-A | ANTIPROLIFERATIVE,-TUMOR AND -CARCINOGENIC AGENTS; ULCERATIVE COLITIS; CROHN*S DISEASE | BOEHRINGER INGELHEIM KG (DE) | 1997-10-07 | — | — | US | disclosed |
| US-5643919-A | TREATMENT OF CROHN*S DISEASE, ULCERATIVE COLITIS | BOEHRINGER INGELHEIM KG (DE) | 1997-07-01 | — | — | US | disclosed |
| WO-1994000435-A1 | RING-CLOSED DIHYDROPYRIDINES AND THEIR USE IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM KG (DE) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142399-A1 | Dual function drugs and uses thereof | COMT, DRD2, SLC6A3 | AOC3 943/4885SMN1; SMN2 4424/4885POLB 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.